PRECLINICAL DATA ON THE IL-4 RECEPTOR ANTAGONIST PRS-060 PRESENTED AT THE EUROPEAN RESPIRATORY SOCIETY CONFERENCE; MARY FITZGERALD, PH.D., TO LEAD PIERIS RESPIRATORY DRUG DEVELOPMENT PROGRAM […]
Code Rebel Corp. (NASDAQ: CDRB) […]
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Wall Street Analyzer’s CEO Interview Series […]
Up to $9.5 Million in Debt Financing and $12 Million in Equity Financing.
Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product Candidates
Lead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority
[…]
Will Also Participate in Additional Wattenberg Well […]
Wall Street Analyzer’s CEO Interview Series […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com